Ibansunate softgel, containing dihydroartemisinin, is indicated for the treatment of malaria; it is contraindicated in patients with known hypersensitivity to the drug or its components, may cause side effects such as dizziness, nausea, and gastrointestinal disturbances, and can interact with drugs that affect liver enzymes, potentially altering their effectiveness.